A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
AbstractThirty-eight patients with advanced breast cancer were treated with oral 4-demethoxydaunorubicin in a continuous weekly schedule at a dose of 15 mg/m2/week. Subjective toxicity consisted of mild nausea (grade 1) in 52% with more severe GI side effects (grade 2) in 15%. Three patients developed grade 1 alopecia and there were no episodes of cardiac failure. Significant neutropenia (grade 2/3) only occurred in patients with marrow involvement or widespread bone disease. There was one CR and 5 PRs, an overall response rate of 15.7% (95% confidence limits 6-31%). In addition 6 patients had disease stabilization for at least 6 months. Fourteen patients progressing on 4-demethoxydaunorubicin have received adriamycin 60 mg/m2 21 days. There have been 5 PRs in this group indicating possible non-cross-resistance between these two agents.
CitationA phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer. 1987, 23 (4):391-4 Eur J Cancer Clin Oncol
JournalEuropean Journal of Cancer & Clinical Oncology
- Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
- Authors: Wander HE, Meyer D, Schuff-Werner P, Nagel GA
- Issue date: 1986 Aug
- Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
- Authors: Bastholt L, Dalmark M
- Issue date: 1987 May
- A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
- Authors: Stuart NS, Cullen MH, Priestman TJ, Blackledge GR, Tyrrell CJ
- Issue date: 1988
- Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
- Authors: Hochster HS, Green MD, Blum RH, Wernz JC, Speyer JL, Muggia FM
- Issue date: 1986
- Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
- Authors: Kolarić K, Mechl Z, Potrebica V, Sopkova B
- Issue date: 1987